Pharmeasy

Thyrocare expands Northern India presence with Polo Labs acquisition

This move will lead to Thyrocare integrating Polo Labs' 14 laboratories spread across Punjab, Haryana, and Himachal Pradesh into its existing network

Online pharmacy PharmEasy raises $216 million at a 90% cut in valuation

According to a report, the Mumbai-based firm has also been trying to raise Rs 3,500 crore since August 2023 to repay the debt it took from Goldman Sachs

Pharmeasy FY23 losses widen 31%, revenue increases 16% to Rs 6,644 cr

Online pharmacy dropped plan for an IPO in 2022, says it is cutting down expenses

PharmEasy bags Rs 1.3K cr from Pai; Rs 3.5K cr rights issue oversubscribed

Besides Pai's commitment, PharmEasy raised the remaining Rs 2,200 crore from existing shareholders

Tata 1mg overtakes PharmEasy as leaders in India's e-pharmacy market

Tata 1mg now holds 31% of the market share, up from 19% in October 2022. PharmEasy's market share decreased to 15% from 33% in the same period

API Holdings' Rs 3,500 cr rights issue oversubscribed: Dhaval Shah

He said in November 2022, the firm had aimed for profitability by April 2023

Lupin's subsidiary, Generic Health gets Tiotropium 18 micrograms approval

The company has received the approval from Therapeutic Goods Administration (TGA)

Manipal Group likely to inject Rs 1,000 cr into PharmEasy for 18% stake

Omnichannel pharmacy chain in talks to raise ~2,400 cr: if successful, will be first fundraise by a unicorn at a discount

PharmEasy to raise Rs 2,400 cr, Manipal Group likely to invest Rs 1,000 cr

The fundraising will be done via a rights issue where the stock will be sold at a 90 per cent discount at Rs 5 per share

Janus Henderson further downgrades PharmEasy valuation to $ 2.7 billion

Several other Indian startups such as Meesho, Swiggy, Byju's, Pine Labs, and Ola have seen similar cuts in their valuations

Janus Henderson marks down PharmEasy's valuation by half to $2.8 bn

Neuberger Berman, another US investor, earlier marked down valuation of shares it holds in online pharmacy's parent

USA's Neuberger Berman slashes valuation of India's Pine Labs, PharmEasy

Fintech firm's valuation cut by 38% and online pharmacy's by 21% as start-up investors battle macroeconomic uncertainties

Drug, medical services firm PharmEasy may lay off hundreds of employees

The company has a total workforce of about 1500

Snapdeal defers $152 mn IPO indefinitely citing poor market conditions

Development follows shelving of IPO plans by several notable firms such as Image Marketing (owner of wearable brand Boat), Droom Technology and PharmEasy

Prosus posts $80-million loss on investment in PayU India

Technology investor Prosus on Wednesday reported widening of its consolidated trading loss to USD 80 million, about Rs 654 crore, on account of investment in PayU India business during first half of the current fiscal. The Netherlands-based investor firm, however, registered a 59 per cent growth in total payments volume (TPV) at USD 28 billion, about Rs 2.29 lakh crore, in India. PayU revenue increased to USD 183 million, about Rs 1,497 crore. "Consolidated trading losses expanded to USD 80 million, as we continued to invest in growing our credit operations in India. In India, our largest payments market, TPV grew 59 per cent to USD 28 billion, and revenue increased 48 per cent to USD 183 million, following increased digitalisation in e-commerce, financial services and bill payments, and a rebound in post pandemic travel," the company said. The Prosus group's overall trading loss widened to USD 1.4 billion during the reported period from USD 2.8 billion a year ago. The revenue of

Withdrawal of start-up IPOs take wind out of sails of unlisted market

Share prices, trading activity slump amid rising uncertainty for startup listings

South Korea's KB Group invests $100 mn in Elev8 Venture Partners Fund

Financing will help Elev8 identify investment opportunities in Indian technology companies

EvolutionX Debt Capital makes maiden investment in PharmEasy parent firm

Debt financing platform's investment amount was not revealed; it will make equity infusion later

Boat joins PharmEasy, Droom to shelve listing plans amid valuation concerns

Rising Sebi scrutiny, poor investor response during roadshows seen as reasons for withdrawal by companies

'Brand Aamir' in the soup over ad controversy. Can he bounce back?

Actor facing flak for ad for AU Small Finance Bank; not new to controversy, which could affect brand value, say experts